EGFR and neoplasm: Based on the results of the network pharmacology analysis, we examined the changes in PI3K/AKT, EGFR and HIF-1 signaling pathways, and the results showed that these pathway-related proteins were not significantly altered, and we speculate that icaritin may exert anti-tumor effects through other pathways (Supplementary Figure S2).